 |
160 Products |  |
813 Diseases | | 160 Products |
|
1608 Trials |  |
78055 News |  |
| «12...888889890891892893894895896897898...903904» |
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Enrollment open, IO biomarker: The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis (clinicaltrials.gov) - Nov 11, 2012
P3, N=20, Recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting
- docetaxel / Generic mfg.
Trial completion, Metastases: Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 11, 2012
P1/2, N=30, Completed, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Rolvedon (eflapegrastim-xnst) / Assertio
New P2 trial: SPI-GCF-12-201: Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer (clinicaltrials.gov) - Nov 8, 2012
P2, N=144, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
- Enrollment change, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2012
P2, N=7, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=44 --> 7
- | Ibrance (palbociclib) / Pfizer
Trial completion: Relative Bioavailability Study (clinicaltrials.gov) - Nov 7, 2012
P1, N=24, Completed, Sponsor: Pfizer
N=44 --> 7 Active, not recruiting --> Completed
- Trial completion, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2012
P2, N=7, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Nplate (romiplostim) / Amgen
Trial completion: Open Label Extension Study of AMG 531 in Japanese Subjects With ITP (clinicaltrials.gov) - Nov 7, 2012
P2/3, N=44, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors (clinicaltrials.gov) - Nov 7, 2012
P2, N=60, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
New P2 trial: NeoPalAna: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Nov 6, 2012
P2, N=29, Recruiting, Sponsor: Washington University School of Medicine
- ||| pasotuxizumab (BAY2010112) / Amgen, Bayer
New P1 trial: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 6, 2012
P1, N=70, Recruiting, Sponsor: Bayer
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients (clinicaltrials.gov) - Nov 6, 2012
P1, N=48, Active, not recruiting, Sponsor: Amgen
- Epogen (epoetin alfa) / Amgen
Trial completion: NEAT: Neonatal Erythropoietin in Asphyxiated Term Newborns (clinicaltrials.gov) - Nov 6, 2012
P1, N=24, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| navtemadlin (KRT-232) / Kartos Therap
New P1 trial, Metastases: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma (clinicaltrials.gov) - Nov 5, 2012
P1, N=107, Recruiting, Sponsor: Amgen
- || trebananib (AMG 386) / Amgen
Enrollment closed: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Nov 4, 2012
P1, N=103, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Effect of Darbepoetin in Contrast-induced Nephropathy (clinicaltrials.gov) - Nov 1, 2012
P2/3, N=330, Recruiting, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Active, not recruiting N=150 --> 330
- |||| oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Nov 1, 2012
P1/2, N=349, Recruiting, Sponsor: Onyx Therapeutics, Inc.
N=150 --> 330 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial termination: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 29, 2012
P1/2, N=73, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Completed --> Terminated; Trial completed prematurely.
- bortezomib / Generic mfg., ifosfamide / Generic mfg., vinorelbine tartrate / Generic mfg.
Trial completion, Combination therapy: Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy (clinicaltrials.gov) - Oct 29, 2012
P2, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Trial completed prematurely. Suspended --> Completed
- | Vectibix (panitumumab) / Amgen
New P2 trial: Ensayo de fase II de un r (EUDRACT) - Oct 28, 2012
P2, N=61, Ongoing, Sponsor: Grupo Espa
- | Vectibix (panitumumab) / Amgen
New P1/2 trial: Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Oct 28, 2012
P1/2, N=108, Recruiting, Sponsor: Hellenic Oncology Research Group
- Enbrel (etanercept) / Pfizer, Amgen
New P1 trial: Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 28, 2012
P1, N=12, Recruiting, Sponsor: Life Extension Foundation Inc.
- ||||||| Prolia (denosumab) / Amgen
Trial completion: Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis (clinicaltrials.gov) - Oct 28, 2012
P3, N=242, Completed, Sponsor: Amgen
Suspended --> Completed Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Study to Evaluate the Safety and Efficacy of Denosumab and Actonel (clinicaltrials.gov) - Oct 28, 2012
P3, N=870, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 28, 2012
P1/2, N=138, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| dulanermin (AMG 951) / Amgen, Roche
Trial completion: A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab (clinicaltrials.gov) - Oct 28, 2012
P2, N=213, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| brazikumab (AMG 139) / AstraZeneca
New P2 trial: Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. (clinicaltrials.gov) - Oct 24, 2012
P2, N=224, Active, not recruiting, Sponsor: AstraZeneca
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 24, 2012
P1, N=12, Recruiting, Sponsor: Life Extension Foundation Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Vectibix (panitumumab) / Amgen
Trial completion: PaLiDo: Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type (clinicaltrials.gov) - Oct 24, 2012
P2, N=33, Completed, Sponsor: Vejle Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Enrollment open: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Oct 23, 2012
P2, N=80, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Neulapeg (pegfilgrastim biosimilar) / GC Biopharma
Enrollment change: GCPGC in Chemotherapy-induced Neutropenia (clinicaltrials.gov) - Oct 22, 2012
P2/3, N=177, Completed, Sponsor: Green Cross Corporation
Not yet recruiting --> Recruiting N=60 --> 177
- || Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2/3 trial: HBP-Neupogen: Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim) (clinicaltrials.gov) - Oct 22, 2012
P2/3, N=59, Completed, Sponsor: Helsinki University Central Hospital
- | Lemtrada (alemtuzumab) / Sanofi
New P1/2 trial: CAM-THY: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2012
P1/2, N=86, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- || Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change: Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=72, Completed, Sponsor: Amgen
N=60 --> 177 N=250 --> 72
- ||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
New P2 trial: NOLAN: Naproxen or Loratadine and Neulasta (clinicaltrials.gov) - Oct 21, 2012
P2, N=600, Recruiting, Sponsor: Amgen
- ||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=72, Completed, Sponsor: Amgen
N=250 --> 72 Active, not recruiting --> Completed
- | plerixafor / Generic mfg.
New P1 trial: Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease (clinicaltrials.gov) - Oct 18, 2012
P1, N=15, Recruiting, Sponsor: Proteonomix, Inc.
- Epogen (epoetin alfa) / Amgen
Trial withdrawal, Metastases: Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Completed --> Withdrawn
- Enrollment change, Metastases: Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium (clinicaltrials.gov) - Oct 17, 2012
P2, N=65, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Withdrawn N=49 --> 65
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=30, Completed, Sponsor: University of California, San Francisco
N=49 --> 65 Recruiting --> Completed
- Ibrance (palbociclib) / Pfizer
New P2 trial: Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women (clinicaltrials.gov) - Oct 16, 2012
P2, N=45, Recruiting, Sponsor: Organisation for Oncology and Translational Research
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - Oct 16, 2012
P3, N=200, Completed, Sponsor: Amgen
Recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment closed, IO biomarker: CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 (clinicaltrials.gov) - Oct 14, 2012
P2, N=145, Active, not recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| AMG 167 / UCB, Amgen
Trial completion: An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - Oct 14, 2012
P1, N=74, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Fiprima (filgrastim biosimilar) / Eurofarma
Trial completion, Head-to-Head: A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer (clinicaltrials.gov) - Oct 14, 2012
P3, N=220, Completed, Sponsor: Eurofarma Laboratorios S.A.
Active, not recruiting --> Completed Recruiting --> Completed
- cyclophosphamide / Generic mfg., decitabine / Generic mfg.
New P2 trial: Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 11, 2012
P2, N=20, Recruiting, Sponsor: University of Wisconsin, Madison
- | FP-1039 / Amgen
Trial suspension, Combination therapy, Metastases: A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - Oct 10, 2012
P1b, N=54, Suspended, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Completed Not yet recruiting --> Suspended
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial withdrawal: Infusion of Expanded Cord Blood T Cells (clinicaltrials.gov) - Oct 9, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Suspended Terminated --> Withdrawn
- | Vectibix (panitumumab) / Amgen
New P2 trial: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Oct 9, 2012
P2, N=80, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- | Enrollment open: High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (clinicaltrials.gov) - Oct 9, 2012
P3, N=2000, Recruiting, Sponsor: St. Anna Kinderkrebsforschung
Terminated --> Withdrawn Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal: Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Oct 8, 2012
P2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Terminated --> Withdrawn